Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 648-653

  Wueppenhorst, Nicole ^a   Stueger, Hans Peter ^b   Kist, Manfred ^a   Glocker, Erik ^a,c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b AUSTRIAN AGENCY FOR HEALTH AND FOOD SAFETY   (Austria)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

16S rRNA; 23S rRNA; gyrA; Multiresistance; Mutations; rpoB; Treatment failure

Indexed keywords

AMOXICILLIN; BACTERIAL RNA; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFAMPICIN; RNA 16S; RNA 23S; RNA POLYMERASE BETA SUBUNIT; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; GENE MUTATION; GERMANY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GERMANY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; RNA, RIBOSOMAL, 23S;

EID: 62549166681     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp003     Document Type: Article

References (41)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
2. Blaser MJ, Atherton JC. Helicobacter pylori persistence: Biology and disease. J Clin Invest 2004; 113: 321-33.
3. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol 2006; 1: 63-96.
4. De Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 2007; 12 Suppl 2: 22-31.
5. Malfertheiner P, Mégraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: Th e Maastricht III Consensus Report. Gut 2007; 56: 772-81.
6. Perri F, Festa V, Clemente R et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimen. Aliment Pharmacol Ther 2001; 14: 311-6.
7. Gisbert JP, Pajares JM. Helicobacter pylori 'rescue' therapy after failure of two eradication treatments. Helicobacter 2005; 10 363-72.
8. Toracchio S, Capodicasa S, Soraja DB et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33-8.
9. Gisbert JP, Bermejo F, Castro-Fernandez M et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: A Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103: 71-6.
10. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
11. Perna F, Zullo A, Ricci C et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: Role of bacterial resistance. Dig Liver Dis 2007; 39: 1001-5.
12. Carothers JJ, Bruce MG, Hennessy TW et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007; 44: e5-8.
13. Glocker E, Bogdan C, Kist M. Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany. J Antimicrob Chemother 2007; 59: 874-9.
14. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51: 346-9.
15. Kim JM, Kim JS, Kim N et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005; 56: 965-7.
16. Bogaerts P, Berhin C, Nizet H et al. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006; 11: 441-5.
17. Cattoir V, Nectoux J, Lascols C et al. Update on fluoroquinolone resistance in Helicobacter pylori: New mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007; 29: 389-96.
18. Lee CC, Lee VW, Chan FK et al. Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008; 54: 50-3.
19. Kist M, Glocker E. ResiNet - a nationwide German sentinel study for surveillance and analysis of antimicrobial resistance in Helicobacter pylori. Euro Surveill 2004; 8: Article 4.
20. Kist M. Isolation and identification of bacteria of the genera Campylobacter and Helicobacter. Zentralbl Bakteriol 1991; 276: 124-39.
21. Glupczynski Y, Mégraud F, Lopez-Brea M et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
22. Glupczynski Y, Broutet N, Cantagrel A et al. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-52.
23. Matsumura M, Hikiba Y, Ogura K et al. Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol 2001; 39: 691-5.
24. Glocker E, Berning M, Gerrits MM et al. Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori. Antimicrob Agents Chemother 2005; 49: 3166-70.
25. Wang G, Wilson TJ, Jiang Q et al. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001; 45: 727-33.
26. Gerrits MM, Berning M, Van Vliet AHM et al. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47: 2984-6.
27. Heep M, Lehn N, Brandstaetter B et al. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 143-5.
28. Tankovic J, Lascols C, Sculo Q et al. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47: 3942-4.
29. Glupczynski Y, Labbe M, Burette A et al. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet 1987; 1: 1096.
30. Stone JW, Wise R, Donovan IA et al. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. J Antimicrob Chemother 1988; 22: 92-3.
31. Megraud F. H. pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
32. Megraud F. Helicobacter pylori and antimicrobial resistance. Gut 2007; 56: 1502.
33. Romano M, Marmo R, Cuomo A et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1: 273-8.
34. Miwa H, Nagahara A, Kurosawa A et al. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003; 17: 1545-51.
35. Neri M, Milano A, Di Bonaventura G et al. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Aliment Pharmacol Ther 2003; 18: 821-7.
36. Glocker E, Kist M. Emergence of a Helicobacter pylori isolate with reduced susceptibility to tetracycline in Germany. J Antimicrob Chemother 2007; 58: 1103-4.
37. van Doorn LJ, Schneeberger PM, Nouhan L et al. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-6.
38. Suzuki T, Matsuo K, Sawaki A et al. Systematic review and meta-analysis: Importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 273-80.
39. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8.
40. Schwab M, Schaeffeler E, Klotz U et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-9.
41. Furuta T, Shirai N, Xiao F et al. Polymorphism of interleukin-β affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2004; 2: 22-30.